Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mRNA-1982 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose-finding Phase | EXPERIMENTAL | Participants will receive mRNA-1982 or placebo as an intramuscular injection. |
| Booster Phase | EXPERIMENTAL | Participants will receive mRNA-1982 (as a booster) or placebo as an intramuscular injection. |
| Name | Type | Description |
|---|---|---|
| mRNA-1982 | BIOLOGICAL | Suspension for injection |
| Placebo | BIOLOGICAL | Suspension for injection |
Key Inclusion Criteria: * In good general health in the opinion of the investigator as determined by medical evaluation including medical history and physical examination at screening. * Contraceptive use by participants should be consistent with local regulations regarding the methods of contracep...
Top 20 of 30 competitors
mRNA-1982 is an investigational vaccine being developed to prevent Lyme disease. It is designed for use in healthy adults aged 18 to 70 years. The vaccine is currently in Phase 2 clinical development and has not been approved for any indication.
mRNA-1982 is being developed by Moderna, Inc., which trades on the Nasdaq under the ticker symbol MRNA. Moderna is the sponsor of the clinical program evaluating the vaccine for the prevention of Lyme disease.
mRNA-1982 is in Phase 2 clinical development. The only trial listed for this vaccine is a Phase 2 study, and it is currently active but not recruiting. The vaccine remains investigational and has not been approved by the FDA or any other regulatory agency.
mRNA-1982 is being evaluated in one clinical trial: NCT07561294, titled "A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)." The trial is a controlled Phase 2 study with 366 participants, conducted in Canada, and is currently active but not recruiting.
Yes, mRNA-1982 is an mRNA-based vaccine candidate intended to prevent Lyme disease. It is being tested in healthy volunteers aged 18 to 70 years to assess safety, reactogenicity, and immune response. The vaccine is still in clinical development and is not yet approved for use.